Immuneering Updates Clinical Data on Atebimetinib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Immuneering announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. The data are being presented in an oral session at the 2026 American Society of Clinical Oncology, or ASCO. The presentation showcases data from an expanded cohort totaling 55 first-line pancreatic cancer patients. This open-label, single-arm Phase 2a trial evaluated atebimetinib at 320 mg once daily in combination with mGnP in participants with first-line metastatic pancreatic cancer, irrespective of mutational status. The company reported the following as of the April 24 data cutoff date. In the expanded 55-patient cohort, median overall survival was 17.3 months, compared to 8.5 months median overall survival in the pivotal Phase 3 MPACT study of standard of care gemcitabine/nab-paclitaxel. The median follow-up was 11.6 months. Median progression-free survival was 8.3 months, disease control rate was 82%, and the confirmed overall response rate was 36%. In the original 34-patient cohort with longer follow-up, median overall survival was also observed to be 17.3 months - supporting the consistency of the survival signal across cohorts with different durations of follow-up. Only two categories of Grade 3 or higher treatment-related adverse events occurred in at least 10% of participants, both related to chemotherapy. No Grade 4 adverse events related to atebimetinib and no Grade 5 treatment-related adverse events were reported. Only one participant discontinued atebimetinib while continuing mGnP. The safety profile observed in the trial compared favorably to historical experiences with intensive chemotherapy treatments and combination regimens under development in pancreatic cancer. Additionally, 84% of participants with available data maintained or gained weight at three months, a potentially important indicator of preserved performance status and tolerability in this patient population where cachexia is common and correlated with poorer outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMRX
Wall Street analysts forecast IMRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.480
Low
11.00
Averages
14.50
High
20.00
Current: 4.480
Low
11.00
Averages
14.50
High
20.00
About IMRX
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immuneering Reports Phase 2a Trial Results for Atebimetinib
- Trial Results: Immuneering Corporation presented Phase 2a trial results at the 2026 ASCO annual meeting, revealing that the combination of Atebimetinib and modified gemcitabine nab paclitaxel (mGnP) resulted in a median overall survival of 17.3 months in 55 patients, more than double the 8.5 months observed with mGnP alone, indicating significant potential in treating metastatic pancreatic ductal carcinoma.
- Efficacy Metrics: The trial also reported a median progression-free survival of 8.3 months, a disease control rate of 82%, and an objective response rate of 36%, suggesting that Atebimetinib may provide more durable anti-tumor activity and delay disease progression for patients.
- Safety Profile: The safety profile was manageable, with only two Grade 3 adverse events reported in about 10% of participants, and 84% of patients either maintained or gained weight during treatment, indicating good tolerability and potential for improved quality of life.
- Future Research Plans: The company is actively recruiting for the global, randomized Phase 3 MAPKeeper 301 trial to assess the Atebimetinib and mGnP combination, with the first patient expected to be dosed in mid-2026 and topline data anticipated in mid-2028, demonstrating ongoing commitment to advancing cancer treatment options.
See More
Immuneering Shares Plunge After Pancreatic Cancer Drug Data Release
- Clinical Data Update: Immuneering presented updated data for its pancreatic cancer drug atebimetinib at the ASCO 2026 Annual Meeting, revealing a median overall survival of 17.3 months for first-line metastatic pancreatic cancer patients, significantly exceeding the historical average of 8.5 months for standard chemotherapy, indicating the drug's potential efficacy.
- Trial Phase Advancement: The company is moving atebimetinib into a larger randomized Phase 3 trial, expected to begin dosing patients in mid-2026, which could lay the groundwork for future market applications and enhance treatment options for patients.
- Market Reaction: Despite the positive data, Immuneering's shares plummeted approximately 23% following the announcement, reflecting market concerns over a “sell the news” scenario, especially after a 14% rise on the previous trading day, potentially marking the stock's worst day since January.
- Analyst Ratings Optimistic: According to Koyfin, all six analysts covering IMRX rate it as 'Buy' or higher, with an average 12-month price target of $17, representing a potential upside of about 195% from the last closing price, indicating strong market confidence in the company's future prospects.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Immuneering Reports Promising Phase 2a Data for Metastatic Pancreatic Cancer Treatment
- Clinical Trial Progress: Immuneering Corporation's Phase 2a trial for metastatic pancreatic cancer involved 56 patients treated with Atebimetinib in combination with mGnP, revealing a median overall survival of 17.3 months, indicating the drug's potential efficacy and offering new treatment options for patients.
- Adverse Event Monitoring: The only Grade-3 adverse events reported were anemia and neutropenia associated with chemotherapy, suggesting that Atebimetinib's safety profile is relatively manageable, laying a foundation for its future clinical applications.
- Future Research Plans: The company is currently recruiting patients for the Phase 3 MAPKeeper 301 trial, expecting to dose the first patient by mid-2026, demonstrating its ongoing commitment and investment in pancreatic cancer treatment research and development.
- Market Reaction: IMRX shares closed up 3.98% at $5.22 on Thursday, with after-hours trading rising 4.21% to $5.44, reflecting positive investor sentiment towards the clinical data, which may drive future funding and R&D advancements.
See More
Immuneering Reports Clinical Trial Data for Pancreatic Cancer
- Significant Survival Improvement: Immuneering reported a median overall survival of 17.3 months for first-line metastatic pancreatic cancer patients in its Phase 2a trial, indicating the drug's potential to extend patient life and possibly change treatment standards.
- Adverse Event Monitoring: Among treated patients, only 16% experienced anemia and 18% experienced neutropenia, both Grade 3 or higher treatment-related adverse events, suggesting good tolerability of the treatment regimen, which may attract more patients.
- ASCO Conference Presentation: The company will present complete data from 55 patients at the ASCO Annual Meeting on June 1, 2026, covering key metrics such as overall survival and progression-free survival, which is expected to garner significant attention from investors and the medical community.
- Follow-up Research Plans: Immuneering is currently recruiting patients for its pivotal Phase 3 MAPKeeper 301 clinical trial, aimed at further validating the efficacy of atebimetinib, demonstrating the company's ongoing commitment and strategic positioning in cancer treatment.
See More
Immuneering Q1 Earnings Beat Expectations
- Earnings Beat: Immuneering reported a Q1 GAAP EPS of -$0.21, exceeding market expectations by $0.04, indicating some resilience in financial performance despite ongoing losses.
- Cash Position Decline: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $198.6 million, down from $217.0 million as of December 31, 2025, reflecting operational expenditure pressures.
- Optimistic Financial Guidance: Based on the cash position as of March 31, 2026, and current operational plans, the company expects its cash runway to be sufficient to fund operations into 2029, demonstrating confidence in financial management.
- Increased Market Attention: Following the earnings release, Immuneering's market attention has risen, with Seeking Alpha's Quant Rating expressing optimism about the company's future, potentially attracting more investor interest.
See More
Immuneering Reports Phase 2a Trial Results for Atebimetinib
- Trial Results: Immuneering Corporation presented Phase 2a trial results at the 2026 ASCO annual meeting, revealing that the combination of Atebimetinib and modified gemcitabine nab paclitaxel (mGnP) resulted in a median overall survival of 17.3 months in 55 patients, more than double the 8.5 months observed with mGnP alone, indicating significant potential in treating metastatic pancreatic ductal carcinoma.
- Efficacy Metrics: The trial also reported a median progression-free survival of 8.3 months, a disease control rate of 82%, and an objective response rate of 36%, suggesting that Atebimetinib may provide more durable anti-tumor activity and delay disease progression for patients.
- Safety Profile: The safety profile was manageable, with only two Grade 3 adverse events reported in about 10% of participants, and 84% of patients either maintained or gained weight during treatment, indicating good tolerability and potential for improved quality of life.
- Future Research Plans: The company is actively recruiting for the global, randomized Phase 3 MAPKeeper 301 trial to assess the Atebimetinib and mGnP combination, with the first patient expected to be dosed in mid-2026 and topline data anticipated in mid-2028, demonstrating ongoing commitment to advancing cancer treatment options.
See More
Immuneering Shares Plunge After Pancreatic Cancer Drug Data Release
- Clinical Data Update: Immuneering presented updated data for its pancreatic cancer drug atebimetinib at the ASCO 2026 Annual Meeting, revealing a median overall survival of 17.3 months for first-line metastatic pancreatic cancer patients, significantly exceeding the historical average of 8.5 months for standard chemotherapy, indicating the drug's potential efficacy.
- Trial Phase Advancement: The company is moving atebimetinib into a larger randomized Phase 3 trial, expected to begin dosing patients in mid-2026, which could lay the groundwork for future market applications and enhance treatment options for patients.
- Market Reaction: Despite the positive data, Immuneering's shares plummeted approximately 23% following the announcement, reflecting market concerns over a “sell the news” scenario, especially after a 14% rise on the previous trading day, potentially marking the stock's worst day since January.
- Analyst Ratings Optimistic: According to Koyfin, all six analysts covering IMRX rate it as 'Buy' or higher, with an average 12-month price target of $17, representing a potential upside of about 195% from the last closing price, indicating strong market confidence in the company's future prospects.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Immuneering Reports Promising Phase 2a Data for Metastatic Pancreatic Cancer Treatment
- Clinical Trial Progress: Immuneering Corporation's Phase 2a trial for metastatic pancreatic cancer involved 56 patients treated with Atebimetinib in combination with mGnP, revealing a median overall survival of 17.3 months, indicating the drug's potential efficacy and offering new treatment options for patients.
- Adverse Event Monitoring: The only Grade-3 adverse events reported were anemia and neutropenia associated with chemotherapy, suggesting that Atebimetinib's safety profile is relatively manageable, laying a foundation for its future clinical applications.
- Future Research Plans: The company is currently recruiting patients for the Phase 3 MAPKeeper 301 trial, expecting to dose the first patient by mid-2026, demonstrating its ongoing commitment and investment in pancreatic cancer treatment research and development.
- Market Reaction: IMRX shares closed up 3.98% at $5.22 on Thursday, with after-hours trading rising 4.21% to $5.44, reflecting positive investor sentiment towards the clinical data, which may drive future funding and R&D advancements.
See More
Immuneering Reports Clinical Trial Data for Pancreatic Cancer
- Significant Survival Improvement: Immuneering reported a median overall survival of 17.3 months for first-line metastatic pancreatic cancer patients in its Phase 2a trial, indicating the drug's potential to extend patient life and possibly change treatment standards.
- Adverse Event Monitoring: Among treated patients, only 16% experienced anemia and 18% experienced neutropenia, both Grade 3 or higher treatment-related adverse events, suggesting good tolerability of the treatment regimen, which may attract more patients.
- ASCO Conference Presentation: The company will present complete data from 55 patients at the ASCO Annual Meeting on June 1, 2026, covering key metrics such as overall survival and progression-free survival, which is expected to garner significant attention from investors and the medical community.
- Follow-up Research Plans: Immuneering is currently recruiting patients for its pivotal Phase 3 MAPKeeper 301 clinical trial, aimed at further validating the efficacy of atebimetinib, demonstrating the company's ongoing commitment and strategic positioning in cancer treatment.
See More
Immuneering Q1 Earnings Beat Expectations
- Earnings Beat: Immuneering reported a Q1 GAAP EPS of -$0.21, exceeding market expectations by $0.04, indicating some resilience in financial performance despite ongoing losses.
- Cash Position Decline: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $198.6 million, down from $217.0 million as of December 31, 2025, reflecting operational expenditure pressures.
- Optimistic Financial Guidance: Based on the cash position as of March 31, 2026, and current operational plans, the company expects its cash runway to be sufficient to fund operations into 2029, demonstrating confidence in financial management.
- Increased Market Attention: Following the earnings release, Immuneering's market attention has risen, with Seeking Alpha's Quant Rating expressing optimism about the company's future, potentially attracting more investor interest.
See More
